AR062095A1 - Profarmaco de compuesto cinamida - Google Patents
Profarmaco de compuesto cinamidaInfo
- Publication number
- AR062095A1 AR062095A1 ARP070103296A ARP070103296A AR062095A1 AR 062095 A1 AR062095 A1 AR 062095A1 AR P070103296 A ARP070103296 A AR P070103296A AR P070103296 A ARP070103296 A AR P070103296A AR 062095 A1 AR062095 A1 AR 062095A1
- Authority
- AR
- Argentina
- Prior art keywords
- groups
- group
- substituted
- substituents
- different
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 4
- 150000004945 aromatic hydrocarbons Chemical group 0.000 abstract 4
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 150000001450 anions Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Cultivation Of Plants (AREA)
- Seasonings (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Fármaco util para Alzheimer, demencia senil, síndrome de Down o amiloidosis. Reivindicacion 1: Un compuesto caracterizado por la formula (1) o su sal aceptable para uso farmacologico: donde Ra y Rb son iguales o diferentes y cada uno representa un átomo de hidrogeno o un grupo alquilo C1-6; Xa representa un grupo metoxi o un átomo de fluor; Y representa CO(O)nRcÎ Ma, donde R representa un grupo alquilo C1-6, un grupo anular hidrocarbonado aromático de 6 a 14 miembros, un grupo heterocíclico aromático de 5 a 14 miembros, un grupo anular hidrocarbonado no aromático de 6 a 14 miembros, o un grupo heterocíclico no aromático de 5 a 14 miembros, que puede estar sustituido con los mismos o diferentes 1 a 5 sustituyentes seleccionados del grupo de sustituyentes A1; n es 0 o 1; y Ma representa un anion, -P(=O)(ORd)2ÎMa, donde Rd, representa un grupo alquilo C1-6 que puede estar sustituido con los mismos o diferentes 1 a 3 sustituyentes seleccionados del grupo de sustituyentes A2, y Ma representa un anion, -P(=O)(OH)2ÎMa, donde Ma representa un anion, -P(=O)(O-)(OH) o -P(=O) (-O-)(-OÎMb+), donde Mb+ representa un cation; A está representado por la formula (2) donde (a) R1, R2, R3, y R4 son iguales o diferentes y cada uno representa un átomo de hidrogeno o un grupo alquilo C1-6, X1 representa un grupo alquileno C1-6 que puede estar sustituido con 1 a 3 grupos hidroxi o alquilo C1-6 que pueden estar sustituidos con 1 a 3 grupos hidroxi, X2 representa un átomo de oxígeno o un grupo metileno que puede estar sustituido con 1 o 2 grupos alquilo C1-6, y Ar1 representa -X1-a-Ar1-a, donde Ar1-a representa un anillo hidrocarbonado aromático de 6 a 14 miembros o un grupo heterocíclico aromático de 5 a 14 miembros, que puede estar sustituido con los mismos o diferentes 1 a 3 sustituyentes seleccionados del grupo de sustituyentes A2, y X1-a representa un enlace simple o un átomo de oxígeno; o (b) R1, R2, R3, R4, y X2 son lo definido con anterioridad, y Ar1-X1- representa un grupo cicloalquilo C3-8 que tiene un grupo metileno que puede estar sustituido con un átomo de oxígeno condensado con un anillo bencénico que puede estar sustituido con los mismos o diferentes 1 a 3 sustituyentes seleccionados del grupo de sustituyentes A2, o A está representado por la formula (3) donde ---- representa un enlace simple o un doble enlace; Ar2 representa un anillo hidrocarbonado aromático de 6 a 14 miembros o un grupo heterocíclico aromático de 5 a 14 miembros, que puede estar sustituido con los mismos o diferentes 1 a 3 sustituyentes seleccionados del grupo de sustituyentes A2; R5 y R6 son iguales o diferentes y cada uno representa un sustituyente seleccionado del grupo de sustituyentes A2; Z1 y Z2 son iguales o diferentes y cada uno representa un grupo metileno o vinileno, que puede estar sustituido con los mismos o diferentes 1 o 2 sustituyentes seleccionados del grupo de sustituyentes A2, un átomo de oxígeno, o un grupo imino que puede estar sustituido con un grupo alquilo C1-6 o acilo C1-6; y p, q y r son iguales o diferentes y cada uno representa un numero entero de 0 a 2, donde: el grupo de sustituyentes A1 consiste en (1) grupos hidroxi, (2) grupos ciano, (3) grupos cicloalcoxi C3- 8, (4) grupos alcoxi C1-6 que pueden estar sustituidos cada uno con 1 a 3 sustituyentes seleccionados del grupo que consiste en átomos de halogeno, grupos hidroxi, grupos ciano, grupos cicloalquilo C3-8 y grupos cicloalcoxi C3-8, (5) grupos amino que pueden estar sustituidos cada uno con 1 o 2 grupos alquilo C1-6 que pueden estar sustituidos cada uno con 1 a 3 átomos de halogeno, (6) grupos carbamoílo que pueden estar sustituidos cada uno con 1 o 2 grupos alquilo C1-6 que pueden estar sustituidos cada uno con 1 a 3 átomos de halogeno, (7) grupos carboxilo, (8) grupos piridinilo, y (9) residuos de azucares; y el grupo de sustituyentes A2 consiste en (1) átomos de halogeno, (2) grupos hidroxi, (3) grupos ciano, (4) grupos cicloalquilo C3-8, (5) grupos cicloalcoxi C3-8, (6) grupos alquilo C1-6 que pueden estar sustituidos cada uno con 1 a 3 sustituyentes seleccionados del grupo que consiste en átomos de halogeno, grupos hidroxi, grupos ciano, grupos cicloalquilo C3-8, grupos alcoxi C1-6, y grupos cicloalcoxi C3-8, (7) grupos alcoxi C1-6 que pueden estar sustituidos cada uno con 1 a 3 sustituyentes seleccionados del grupo que consiste en átomos de halogeno, grupos hidroxi, grupos ciano, grupos cicloalquilo C3-8, y grupos cicloalcoxi C3-8, (8) grupos amino que pueden estar sustituidos cada uno con 1 o 2 grupos alquilo C1-6 que pueden estar sustituidos cada uno con 1 a 3 átomos de halogeno, y (9) grupos carbamoílo que pueden estar sustituidos cada uno con 1 o 2 grupos alquilo C1-6 que pueden estar sustituidos cada uno con 1 a 3 átomos de halogeno.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82076106P | 2006-07-28 | 2006-07-28 | |
| JP2006206007 | 2006-07-28 | ||
| US86925906P | 2006-12-08 | 2006-12-08 | |
| JP2006331274 | 2006-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062095A1 true AR062095A1 (es) | 2008-10-15 |
Family
ID=38981524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103296A AR062095A1 (es) | 2006-07-28 | 2007-07-25 | Profarmaco de compuesto cinamida |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7737141B2 (es) |
| EP (1) | EP2048143A4 (es) |
| JP (1) | JPWO2008013213A1 (es) |
| KR (1) | KR20090033910A (es) |
| AR (1) | AR062095A1 (es) |
| AU (1) | AU2007277729A1 (es) |
| CA (1) | CA2658037A1 (es) |
| CO (1) | CO6150153A2 (es) |
| CR (1) | CR10499A (es) |
| EA (1) | EA200970172A1 (es) |
| EC (1) | ECSP099091A (es) |
| GE (1) | GEP20115176B (es) |
| HN (1) | HN2009000157A (es) |
| IL (1) | IL196351A0 (es) |
| MA (1) | MA30636B1 (es) |
| MX (1) | MX2008015504A (es) |
| MY (1) | MY144971A (es) |
| NO (1) | NO20090541L (es) |
| NZ (1) | NZ574102A (es) |
| PE (1) | PE20080281A1 (es) |
| SA (1) | SA07280403B1 (es) |
| SV (1) | SV2009003157A (es) |
| TN (1) | TN2009000024A1 (es) |
| TW (1) | TW200821319A (es) |
| WO (1) | WO2008013213A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| KR20070083781A (ko) * | 2004-10-26 | 2007-08-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물의 비정질체 |
| JPWO2007058304A1 (ja) * | 2005-11-18 | 2009-05-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド化合物の塩またはそれらの溶媒和物 |
| KR20080076907A (ko) * | 2005-11-18 | 2008-08-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 유도체의 제조 방법 |
| TWI370130B (en) * | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| MY144960A (en) * | 2005-11-24 | 2011-11-30 | Eisai R&D Man Co Ltd | Morpholine type cinnamide compound |
| TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| US7737141B2 (en) | 2006-07-28 | 2010-06-15 | Eisai R&D Management Co., Ltd. | Prodrug of cinnamide compound |
| CL2008000582A1 (es) * | 2007-02-28 | 2008-06-27 | Eisai R&D Man Co Ltd | Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis. |
| KR20100016580A (ko) * | 2007-05-16 | 2010-02-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 유도체의 원폿 제조 방법 |
| US7935815B2 (en) * | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| KR20100055456A (ko) | 2007-08-31 | 2010-05-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 다환식 화합물 |
| EP2234954B1 (en) | 2007-12-20 | 2015-02-18 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
| KR101204213B1 (ko) | 2007-12-21 | 2012-11-26 | 에프. 호프만-라 로슈 아게 | 오렉신 수용체 길항제로서의 헤테로아릴 유도체 |
| WO2009087127A1 (en) | 2008-01-11 | 2009-07-16 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| CN101925607A (zh) * | 2008-01-28 | 2010-12-22 | 卫材R&D管理有限公司 | 结晶性的肉桂酰胺化合物或其盐 |
| EP2257541B1 (en) | 2008-02-22 | 2013-08-14 | F. Hoffmann-La Roche AG | Modulators for amyloid beta |
| WO2010040661A1 (en) | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| AU2009312856A1 (en) | 2008-11-10 | 2010-05-14 | F. Hoffmann-La Roche Ag | Heterocyclic gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| CA2803825C (en) * | 2010-07-02 | 2015-12-29 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| WO2012096458A2 (en) | 2011-01-13 | 2012-07-19 | Bio-Pharm Solutions Co., Ltd. | Process for preparation of phenyl carbamate derivatives |
| ES2555872T3 (es) | 2011-06-15 | 2016-01-11 | Basf Se | Poliésteres ramificados con grupos sulfonato |
| US8901066B2 (en) | 2011-06-15 | 2014-12-02 | Basf Se | Branched polyesters with sulfonate groups |
| CA2859129C (en) * | 2011-12-27 | 2020-07-14 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating epilepsy |
| JP6126251B2 (ja) * | 2013-03-12 | 2017-05-10 | バイオ−ファーム ソリューションズ カンパニー リミテッド | フェニルカルバメート化合物及びこれを含む神経ガスによる疾患の予防又は治療用組成物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄａｎｄａｃｏｍｐｏｓｉｔｉｏｎｆｏｒｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇａｎｅｒｖｅｇａｓ−ｉｎｄｕｃｅｄｄｉｓｅａｓｅｃｏｍｐｒｉｓｉｎｇｔｈｅｓａｍｅ｝ |
| WO2014142477A1 (en) | 2013-03-12 | 2014-09-18 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating pediatric epilesy and epilesy-related syndromes |
| EP3552017B1 (en) * | 2016-12-09 | 2022-02-23 | Denali Therapeutics Inc. | Compounds useful as ripk1 inhibitors |
| CN110143935B (zh) * | 2019-06-03 | 2022-09-30 | 华侨大学 | 一种2，5-二取代呋喃衍生物的制备方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3689506D1 (de) * | 1985-10-09 | 1994-02-17 | Shell Int Research | Neue Acrylsäureamide. |
| DE3541716A1 (de) | 1985-11-26 | 1987-05-27 | Celamerck Gmbh & Co Kg | Neue acrylsaeureamide |
| JPH03206042A (ja) | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
| US5281626A (en) | 1990-02-08 | 1994-01-25 | Eisai Co., Ltd. | Benzenesulfonamide derivatives |
| JPH05194517A (ja) | 1992-01-16 | 1993-08-03 | Tanabe Seiyaku Co Ltd | ６−メルカプトプリン誘導体及びその製法 |
| AU680870B2 (en) * | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| AU3577995A (en) | 1994-10-04 | 1996-04-26 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| JPH08283219A (ja) | 1995-04-07 | 1996-10-29 | Eisai Co Ltd | アラルキルアミノアルキルアミド誘導体 |
| EE9800390A (et) | 1996-05-10 | 1999-06-15 | Icos Corporation | Karboliini derivaadid |
| CA2260860A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
| WO1998024785A1 (en) | 1996-12-02 | 1998-06-11 | Fujisawa Pharmaceutical Co., Ltd. | Indole-urea derivatives with 5-ht antagonist properties |
| RU2189982C2 (ru) | 1997-03-31 | 2002-09-27 | Такеда Кемикал Индастриз, Лтд. | Азольные соединения, способ их получения, противогрибковая фармацевтическая композиция и способ лечения грибковой инфекции |
| JP3108997B2 (ja) | 1997-03-31 | 2000-11-13 | 武田薬品工業株式会社 | アゾール化合物、その製造法および用途 |
| NZ505515A (en) | 1997-12-31 | 2003-03-28 | Univ Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
| GB9816984D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
| US6235728B1 (en) * | 1999-02-19 | 2001-05-22 | Bristol-Myers Squibb Company | Water-soluble prodrugs of azole compounds |
| US6967196B1 (en) | 1999-02-26 | 2005-11-22 | Bristol-Myers Squibb Company | Sulfonamide compounds and uses thereof |
| WO2000051981A1 (en) | 1999-03-04 | 2000-09-08 | Nortran Pharmaceuticals Inc. | Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics |
| EP1264820A4 (en) | 2000-03-14 | 2004-09-15 | Fujisawa Pharmaceutical Co | amide compounds |
| US20010051642A1 (en) * | 2000-04-17 | 2001-12-13 | Kyunghye Ahn | Method for treating Alzheimer's disease |
| JP2003531194A (ja) | 2000-04-24 | 2003-10-21 | メルク フロスト カナダ アンド カンパニー | プロスタグランジンｅ阻害薬としてフェニルおよびビアリール誘導体を用いる治療方法および該方法に有用な化合物 |
| CZ20031795A3 (cs) * | 2000-12-04 | 2004-01-14 | F. Hoffmann-La Roche Ag | Fenylethenylové nebo fenylethynylové deriváty jako antagonisté glutamátového receptoru |
| GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| MXPA04005427A (es) * | 2001-12-10 | 2005-04-19 | Amgen Inc | Ligandos de receptor vainilloide y su uso en tratamientos. |
| ATE430727T1 (de) | 2001-12-20 | 2009-05-15 | Bristol Myers Squibb Co | Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren |
| JP2003206280A (ja) | 2001-12-28 | 2003-07-22 | Takeda Chem Ind Ltd | ビアリール化合物およびその用途 |
| DE10211101A1 (de) | 2002-03-14 | 2003-09-25 | Basf Ag | Katalysatoren und Verfahren zur Herstellung von Aminen |
| GB0207436D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| MXPA04011472A (es) * | 2002-05-22 | 2005-02-14 | Amgen Inc | Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor. |
| WO2003101927A1 (en) * | 2002-05-31 | 2003-12-11 | Proteotech, Inc. | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease |
| CA2493374A1 (en) | 2002-07-12 | 2004-01-22 | Aventis Pharma Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| US6900354B2 (en) | 2002-07-15 | 2005-05-31 | Hoffman-La Roche Inc. | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
| EP1594847A2 (en) * | 2003-02-12 | 2005-11-16 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| EP1628666B1 (en) * | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
| AU2004309164B2 (en) | 2003-12-22 | 2007-11-15 | Pfizer Inc. | Triazole derivatives as vasopressin antagonists |
| NZ548208A (en) * | 2004-02-12 | 2010-09-30 | Transtech Pharma Inc | Substituted azole derivatives, compositions, and methods of use |
| MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| KR20070083781A (ko) | 2004-10-26 | 2007-08-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물의 비정질체 |
| US20060241038A1 (en) | 2005-04-20 | 2006-10-26 | Eisai Co., Ltd. | Therapeutic agent for Abeta related disorders |
| WO2007034282A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
| KR20080076907A (ko) * | 2005-11-18 | 2008-08-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 유도체의 제조 방법 |
| JPWO2007058304A1 (ja) | 2005-11-18 | 2009-05-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド化合物の塩またはそれらの溶媒和物 |
| MY144960A (en) * | 2005-11-24 | 2011-11-30 | Eisai R&D Man Co Ltd | Morpholine type cinnamide compound |
| US20070117839A1 (en) * | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
| TWI370130B (en) * | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| AU2007223158B2 (en) | 2006-03-09 | 2012-04-12 | Eisai R & D Management Co., Ltd. | Polycyclic cinnamide derivative |
| TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| US7737141B2 (en) | 2006-07-28 | 2010-06-15 | Eisai R&D Management Co., Ltd. | Prodrug of cinnamide compound |
| EP2117311A4 (en) | 2007-02-08 | 2011-05-11 | Merck Sharp & Dohme | THERAPEUTICS |
| RU2009144998A (ru) | 2007-05-07 | 2011-06-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
| ES2358863T3 (es) * | 2007-05-11 | 2011-05-16 | F. Hoffmann-La Roche Ag | Hetarilanilinas como moduladores de beta-amiloide. |
| US8242150B2 (en) | 2007-06-13 | 2012-08-14 | Merck Sharp & Dohme Corp. | Triazole derivatives for treating alzheimer'S disease and related conditions |
| PE20090957A1 (es) | 2007-08-06 | 2009-07-13 | Schering Corp | Moduladores de gamma secretasa |
-
2007
- 2007-07-25 US US11/878,556 patent/US7737141B2/en not_active Expired - Fee Related
- 2007-07-25 SA SA7280403A patent/SA07280403B1/ar unknown
- 2007-07-25 AR ARP070103296A patent/AR062095A1/es unknown
- 2007-07-26 JP JP2008526796A patent/JPWO2008013213A1/ja not_active Abandoned
- 2007-07-26 CA CA002658037A patent/CA2658037A1/en not_active Abandoned
- 2007-07-26 EP EP07791337A patent/EP2048143A4/en not_active Withdrawn
- 2007-07-26 WO PCT/JP2007/064637 patent/WO2008013213A1/ja active Application Filing
- 2007-07-26 EA EA200970172A patent/EA200970172A1/ru unknown
- 2007-07-26 TW TW096127264A patent/TW200821319A/zh unknown
- 2007-07-26 NZ NZ574102A patent/NZ574102A/en not_active IP Right Cessation
- 2007-07-26 PE PE2007000966A patent/PE20080281A1/es not_active Application Discontinuation
- 2007-07-26 MY MYPI20090056A patent/MY144971A/en unknown
- 2007-07-26 KR KR1020097004007A patent/KR20090033910A/ko not_active Application Discontinuation
- 2007-07-26 MX MX2008015504A patent/MX2008015504A/es not_active Application Discontinuation
- 2007-07-26 AU AU2007277729A patent/AU2007277729A1/en not_active Abandoned
- 2007-07-26 GE GEAP200711078A patent/GEP20115176B/en unknown
-
2008
- 2008-12-11 CR CR10499A patent/CR10499A/es not_active Application Discontinuation
-
2009
- 2009-01-05 IL IL196351A patent/IL196351A0/en unknown
- 2009-01-06 CO CO09000699A patent/CO6150153A2/es unknown
- 2009-01-23 TN TN2009000024A patent/TN2009000024A1/fr unknown
- 2009-01-26 HN HN2009000157A patent/HN2009000157A/es unknown
- 2009-01-27 EC EC2009009091A patent/ECSP099091A/es unknown
- 2009-01-28 SV SV2009003157A patent/SV2009003157A/es unknown
- 2009-02-03 NO NO20090541A patent/NO20090541L/no not_active Application Discontinuation
- 2009-02-11 MA MA31628A patent/MA30636B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SA07280403B1 (ar) | 2010-12-01 |
| US20090048213A1 (en) | 2009-02-19 |
| NZ574102A (en) | 2010-10-29 |
| IL196351A0 (en) | 2009-09-22 |
| MY144971A (en) | 2011-11-30 |
| AU2007277729A1 (en) | 2008-01-31 |
| JPWO2008013213A1 (ja) | 2009-12-17 |
| NO20090541L (no) | 2009-02-03 |
| MA30636B1 (fr) | 2009-08-03 |
| GEP20115176B (en) | 2011-03-10 |
| CA2658037A1 (en) | 2008-01-31 |
| MX2008015504A (es) | 2008-12-18 |
| TN2009000024A1 (en) | 2010-08-19 |
| TW200821319A (en) | 2008-05-16 |
| PE20080281A1 (es) | 2008-05-05 |
| US7737141B2 (en) | 2010-06-15 |
| WO2008013213A1 (fr) | 2008-01-31 |
| EA200970172A1 (ru) | 2009-08-28 |
| KR20090033910A (ko) | 2009-04-06 |
| EP2048143A4 (en) | 2010-11-03 |
| CO6150153A2 (es) | 2010-04-20 |
| HN2009000157A (es) | 2011-01-24 |
| EP2048143A1 (en) | 2009-04-15 |
| SV2009003157A (es) | 2010-01-12 |
| CR10499A (es) | 2009-03-20 |
| ECSP099091A (es) | 2009-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062095A1 (es) | Profarmaco de compuesto cinamida | |
| AR058198A1 (es) | Derivados de morfolina y composiciones farmaceuticas | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR076753A1 (es) | Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides. | |
| AR057915A1 (es) | Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| NO20085140L (no) | Nye indazolderivater som har spiro ringstruktur i sidekjede | |
| ES2694053T3 (es) | Compuestos novedosos como inhibidores de histona desacetilasa 6 y composiciones farmacéuticas que comprenden los mismos | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| AR070993A1 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales como | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| CO6321289A2 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
| CU23706B7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR078776A1 (es) | Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo | |
| ES2526902T3 (es) | Procesos de producción de inhibidores de la girasa y topoisomerasa IV | |
| AR070263A1 (es) | Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR062294A1 (es) | Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| NO20061334L (no) | Indanyl-piperanzinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| AR050153A1 (es) | Beta-agonistas, procedimiento para su preparacion y su uso como medicamentos | |
| EA201170097A1 (ru) | Замещенные трициклические производные против нейродегенеративных заболеваний | |
| CO6251285A2 (es) | Derivado de tetrahidroisoquinolina novedoso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |